Enhanced growth of seed viruses for H5N1 influenza vaccines

Virology

Volumn 366, Issue 1, 2007, Pages 23-27

  Horimoto, Taisuke ^a,c   Murakami, Shin ^a   Muramoto, Yukiko ^a,b   Yamada, Shinya ^a,c   Fujii, Ken ^a,c   Kiso, Maki ^a,c   Iwatsuki Horimoto, Kiyoko ^a,c   Kino, Yoichiro ^d   Kawaoka, Yoshihiro ^a,b,c,e  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d Chemo Sero Therapeutic Research Institute   (Japan)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

H5N1 influenza; Pandemic; Vaccine

Indexed keywords

INFLUENZA VACCINE; SIALIDASE;

ARTICLE; CONTROLLED STUDY; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIROGENESIS; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; CHICK EMBRYO; CHICKENS; GENES, VIRAL; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, INACTIVATED;

SPONDIAS PURPUREA;

EID: 34548186498     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.07.002     Document Type: Article

References (15)

1. Chen Z., Kadowaki S., Hagiwara Y., Yoshikawa T., Matsuo K., Kurata T., and Tamura S. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18 (2000) 3214-3222
2. Dennis C. Flu-vaccine makers toil to boost supply. Nature 440 (2006) 1099
3. Hatta M., Gao P., Halfmann P., and Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293 (2001) 1840-1842
4. Horimoto T., and Kawaoka Y. Influenza: lessons from past pandemic, warnings from current incidents. Nat. Rev., Microbiol. 3 (2005) 591-600
5. Horimoto T., Takada A., Fujii K., Goto H., Hatta M., Watanabe S., Iwatsuki-Horimoto K., Ito M., Tagawa-Sakai Y., Yamada S., Ito H., Ito T., Imai M., Itamura S., Odagiri T., Tashiro M., Lim W., Guan Y., Peiris M., and Kawaoka Y. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24 (2006) 3669-3676
6. Kilbourne E.D., Laver W.G., Schulman J.L., and Webster R.G. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J. Virol. 2 (1968) 281-288
7. Kobasa D., Takada A., Shinya K., Hatta M., Halfmann P., Theriaut S., Suzuki H., Nishimura H., Mitamura K., Sugaya N., Usui T., Murata T., Maeda Y., Watanabe S., Suresh M., Suzuki T., Suzuki Y., Feldmann H., and Kawaoka Y. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431 (2004) 703-707
8. Lu B., Zhou H., Ye D., Kemble G., and Jin H. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. J. Virol. 79 (2005) 6763-6771
9. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., Hughes M., Perez D.R., Donis R., Hoffmann E., Hobom G., and Kawaoka Y. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 9345-9350
10. Nicolson C., Major D., Wood J.M., and Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23 (2005) 2943-2952
11. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., Xu X., Lu X., Katz J., Cox N., and Matsuoka Y. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 (2003) 192-200
12. Sugawara K., Nishiyama K., Ishikawa Y., Abe M., Sonoda K., Komatsu K., Horikawa Y., Takeda K., Honda T., Kuzuhara S., Kino Y., Mizokami H., Mizuno K., Oka T., and Honda K. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30 (2002) 303-314
13. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354 (2006) 1343-1351
14. Webby R.J., Perez D.R., Coleman J.S., Guan Y., Knight J.H., Govorkova E.A., McClain-Moss L.R., Peiris J.S., Rehg J.E., Tuomanen E.I., and Webster R.G. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363 (2004) 1099-1103
15. Wood J.M., and Robertson J.S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev., Microbiol. 2 (2004) 842-847